Trade 10x Genomics, Inc. - TXG CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.12 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
10X Genomics Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | 36.84 |
Open* | 37.02 |
1-Year Change* | -25.54% |
Day's Range* | 37.02 - 38.29 |
52 wk Range | 33.79-63.57 |
Average Volume (10 days) | 1.88M |
Average Volume (3 months) | 23.78M |
Market Cap | 4.97B |
P/E Ratio | -100.00K |
Shares Outstanding | 118.21M |
Revenue | 590.98M |
EPS | -1.91 |
Dividend (Yield %) | N/A |
Beta | 1.94 |
Next Earnings Date | Feb 13, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 28, 2024 | 37.46 | 0.51 | 1.38% | 36.95 | 38.41 | 36.90 |
Mar 27, 2024 | 36.84 | 0.34 | 0.93% | 36.50 | 36.86 | 35.95 |
Mar 26, 2024 | 36.18 | -0.43 | -1.17% | 36.61 | 36.66 | 36.00 |
Mar 25, 2024 | 36.26 | 0.15 | 0.42% | 36.11 | 36.47 | 35.32 |
Mar 22, 2024 | 36.22 | -1.58 | -4.18% | 37.80 | 37.80 | 36.11 |
Mar 21, 2024 | 37.93 | 0.19 | 0.50% | 37.74 | 39.16 | 37.69 |
Mar 20, 2024 | 37.53 | 0.33 | 0.89% | 37.20 | 37.83 | 36.20 |
Mar 19, 2024 | 37.35 | 1.84 | 5.18% | 35.51 | 37.47 | 35.36 |
Mar 18, 2024 | 36.01 | -0.44 | -1.21% | 36.45 | 36.73 | 35.78 |
Mar 15, 2024 | 36.25 | -0.49 | -1.33% | 36.74 | 37.24 | 36.23 |
Mar 14, 2024 | 37.14 | -1.01 | -2.65% | 38.15 | 38.37 | 36.53 |
Mar 13, 2024 | 38.46 | -0.16 | -0.41% | 38.62 | 39.68 | 38.19 |
Mar 12, 2024 | 39.09 | -1.01 | -2.52% | 40.10 | 40.20 | 38.68 |
Mar 11, 2024 | 40.28 | 0.77 | 1.95% | 39.51 | 40.71 | 39.48 |
Mar 8, 2024 | 39.72 | -1.44 | -3.50% | 41.16 | 42.79 | 39.45 |
Mar 7, 2024 | 40.88 | -0.40 | -0.97% | 41.28 | 42.20 | 40.77 |
Mar 6, 2024 | 41.23 | -2.29 | -5.26% | 43.52 | 43.92 | 41.20 |
Mar 5, 2024 | 43.38 | -0.52 | -1.18% | 43.90 | 44.35 | 43.07 |
Mar 4, 2024 | 44.71 | -0.57 | -1.26% | 45.28 | 45.30 | 43.38 |
Mar 1, 2024 | 45.50 | -1.01 | -2.17% | 46.51 | 46.78 | 45.18 |
10x Genomics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, May 1, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q1 2024 10X Genomics Inc Earnings Release Q1 2024 10X Genomics Inc Earnings ReleaseForecast -Previous - |
Thursday, June 13, 2024 | ||
Time (UTC) 20:30 | Country US
| Event 10X Genomics Inc Annual Shareholders Meeting 10X Genomics Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 516.409 | 490.49 | 298.845 | 245.893 | 146.313 |
Revenue | 516.409 | 490.49 | 298.845 | 245.893 | 146.313 |
Cost of Revenue, Total | 120.386 | 74.091 | 58.468 | 61.033 | 28.661 |
Gross Profit | 396.023 | 416.399 | 240.377 | 184.86 | 117.652 |
Total Operating Expense | 684.353 | 542.743 | 834.508 | 276.466 | 257.077 |
Selling/General/Admin. Expenses, Total | 298.3 | 257.56 | 199.726 | 130.834 | 87.936 |
Research & Development | 265.667 | 211.752 | 570.923 | 83.097 | 109.9 |
Other Operating Expenses, Total | 0 | -0.66 | 1.27 | 1.502 | 30.58 |
Operating Income | -167.944 | -52.253 | -535.663 | -30.573 | -110.764 |
Interest Income (Expense), Net Non-Operating | 6.171 | -0.66 | -0.15 | -0.274 | -1.385 |
Other, Net | -0.198 | -0.802 | 1.337 | -0.186 | -0.249 |
Net Income Before Taxes | -161.971 | -53.715 | -534.476 | -31.033 | -112.398 |
Net Income After Taxes | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Net Income Before Extra. Items | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Total Extraordinary Items | |||||
Net Income | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Income Available to Common Excl. Extra. Items | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Income Available to Common Incl. Extra. Items | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Diluted Net Income | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Diluted Weighted Average Shares | 113.859 | 110.348 | 101.152 | 96.2416 | 93.8497 |
Diluted EPS Excluding Extraordinary Items | -1.45795 | -0.52763 | -5.36552 | -0.32471 | -1.19857 |
Diluted Normalized EPS | -1.45795 | -0.52763 | -5.33904 | -0.32471 | -1.19857 |
Unusual Expense (Income) | 0 | 0 | 4.121 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 146.819 | 134.285 | 156.232 | 131.072 | 114.609 |
Revenue | 146.819 | 134.285 | 156.232 | 131.072 | 114.609 |
Cost of Revenue, Total | 47.207 | 35.895 | 36.827 | 30.377 | 27.704 |
Gross Profit | 99.612 | 98.39 | 119.405 | 100.695 | 86.905 |
Total Operating Expense | 210.177 | 186.273 | 179.328 | 171.068 | 177.726 |
Selling/General/Admin. Expenses, Total | 91.51 | 83.28 | 78.887 | 73.401 | 79.337 |
Research & Development | 71.46 | 67.098 | 63.614 | 67.29 | 70.685 |
Unusual Expense (Income) | 0 | ||||
Other Operating Expenses, Total | 0 | 0 | |||
Operating Income | -63.358 | -51.988 | -23.096 | -39.996 | -63.117 |
Interest Income (Expense), Net Non-Operating | 4.095 | 3.85 | 2.69 | 1.911 | 1.129 |
Other, Net | -1.504 | -1.516 | 3.995 | -1.95 | -1.843 |
Net Income Before Taxes | -60.767 | -49.654 | -16.411 | -40.035 | -63.831 |
Net Income After Taxes | -62.414 | -50.747 | -17.215 | -41.914 | -64.458 |
Net Income Before Extra. Items | -62.414 | -50.747 | -17.215 | -41.914 | -64.458 |
Net Income | -62.414 | -50.747 | -17.215 | -41.914 | -64.458 |
Income Available to Common Excl. Extra. Items | -62.414 | -50.747 | -17.215 | -41.914 | -64.458 |
Income Available to Common Incl. Extra. Items | -62.414 | -50.747 | -17.215 | -41.914 | -64.458 |
Diluted Net Income | -62.414 | -50.747 | -17.215 | -41.914 | -64.458 |
Diluted Weighted Average Shares | 116.708 | 115.62 | 114.767 | 114.112 | 113.575 |
Diluted EPS Excluding Extraordinary Items | -0.53479 | -0.43891 | -0.15 | -0.3673 | -0.56754 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.53479 | -0.43891 | -0.15 | -0.3673 | -0.56754 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 635.035 | 747.591 | 774.366 | 480.84 | 106.236 |
Cash and Short Term Investments | 429.984 | 587.447 | 663.603 | 424.166 | 65.08 |
Cash & Equivalents | 219.746 | 587.447 | 663.603 | 424.166 | 65.08 |
Total Receivables, Net | 104.211 | 85.254 | 51.208 | 33.371 | 29.566 |
Accounts Receivable - Trade, Net | 104.211 | 85.254 | 51.208 | 33.371 | 28.088 |
Total Inventory | 81.629 | 59.966 | 29.959 | 15.27 | 8.57 |
Prepaid Expenses | 16.578 | 13.896 | 13.029 | 8.033 | 3.02 |
Total Assets | 1028.98 | 1018.83 | 929.341 | 605.923 | 124.31 |
Property/Plant/Equipment, Total - Net | 359.21 | 230.41 | 119.823 | 48.821 | 11.127 |
Property/Plant/Equipment, Total - Gross | 428.04 | 279.431 | 150.325 | 67.876 | 25.21 |
Accumulated Depreciation, Total | -68.83 | -49.021 | -30.502 | -19.055 | -14.083 |
Other Long Term Assets, Total | 7.366 | 10.917 | 12.798 | 76.262 | 6.947 |
Total Current Liabilities | 130.957 | 110.357 | 118.126 | 63.049 | 32.362 |
Accounts Payable | 21.599 | 17.351 | 4.709 | 13.028 | 8.792 |
Accrued Expenses | 87.682 | 75.821 | 92.326 | 30.035 | 12.118 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 9.882 | 4.187 | ||
Other Current Liabilities, Total | 21.676 | 17.185 | 21.091 | 10.104 | 7.265 |
Total Liabilities | 223.237 | 201.258 | 190.269 | 185.84 | 101.053 |
Total Long Term Debt | 0 | 0 | 0 | 19.837 | 25.489 |
Long Term Debt | 0 | 19.837 | 25.489 | ||
Other Liabilities, Total | 92.28 | 90.901 | 72.143 | 102.954 | 43.202 |
Total Equity | 805.743 | 817.568 | 739.072 | 420.083 | 23.257 |
Redeemable Preferred Stock | 0 | 243.244 | |||
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.001 |
Additional Paid-In Capital | 1839.4 | 1680.86 | 1544.22 | 682.494 | 11.165 |
Retained Earnings (Accumulated Deficit) | -1029.32 | -863.321 | -805.098 | -262.367 | -231.116 |
Other Equity, Total | -4.335 | 0.022 | -0.05 | -0.046 | -0.037 |
Total Liabilities & Shareholders’ Equity | 1028.98 | 1018.83 | 929.341 | 605.923 | 124.31 |
Total Common Shares Outstanding | 115.195 | 112.515 | 108.486 | 96.2416 | 93.8497 |
Other Current Assets, Total | 2.633 | 1.028 | 16.567 | ||
Intangibles, Net | 22.858 | 25.397 | 22.354 | ||
Goodwill, Net | 4.511 | 4.511 | |||
Short Term Investments | 210.238 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 562.348 | 582.94 | 601.894 | 635.035 | 629.422 |
Cash and Short Term Investments | 356.907 | 391.385 | 418.29 | 429.984 | 452.386 |
Cash & Equivalents | 311.264 | 325.879 | 332.32 | 219.746 | 233.951 |
Total Receivables, Net | 103.847 | 87.685 | 77.94 | 104.211 | 83.549 |
Accounts Receivable - Trade, Net | 103.847 | 87.685 | 77.94 | 104.211 | 83.549 |
Total Inventory | 80.917 | 83.687 | 82.307 | 81.629 | 78.629 |
Prepaid Expenses | 20.177 | 18.683 | 20.857 | 16.578 | 14.35 |
Other Current Assets, Total | 0.5 | 1.5 | 2.5 | 2.633 | 0.508 |
Total Assets | 948.54 | 989.638 | 1014.03 | 1028.98 | 996.207 |
Property/Plant/Equipment, Total - Net | 354.2 | 355.962 | 366.844 | 359.21 | 328.789 |
Property/Plant/Equipment, Total - Gross | 448.073 | 441.49 | |||
Accumulated Depreciation, Total | -93.873 | -85.528 | |||
Goodwill, Net | 4.511 | 4.511 | 4.511 | 4.511 | 4.511 |
Intangibles, Net | 21.833 | 22.29 | 22.948 | 22.858 | 23.493 |
Other Long Term Assets, Total | 5.648 | 23.935 | 17.833 | 7.366 | 9.992 |
Total Current Liabilities | 104.717 | 98.087 | 112.006 | 130.957 | 126.855 |
Accounts Payable | 18.836 | 23.124 | 29.317 | 21.599 | 21.594 |
Accrued Expenses | 59.815 | 56.157 | 63.398 | 87.682 | 85.251 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 26.066 | 18.806 | 19.291 | 21.676 | 20.01 |
Total Liabilities | 203.324 | 196.337 | 211.645 | 223.237 | 220.415 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | |||||
Other Liabilities, Total | 98.607 | 98.25 | 99.639 | 92.28 | 93.56 |
Total Equity | 745.216 | 793.301 | 802.385 | 805.743 | 775.792 |
Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Additional Paid-In Capital | 1981.36 | 1936.75 | 1883.93 | 1839.4 | 1793.39 |
Retained Earnings (Accumulated Deficit) | -1235.47 | -1142.48 | -1080.07 | -1029.32 | -1012.11 |
Other Equity, Total | -0.677 | -0.969 | -1.479 | -4.335 | -5.492 |
Total Liabilities & Shareholders’ Equity | 948.54 | 989.638 | 1014.03 | 1028.98 | 996.207 |
Total Common Shares Outstanding | 118.198 | 117.323 | 116.173 | 115.195 | 114.428 |
Short Term Investments | 45.643 | 65.506 | 85.97 | 210.238 | 218.435 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -166 | -58.223 | -542.731 | -31.251 | -112.485 |
Cash From Operating Activities | -33.606 | -21.373 | -217.898 | 34.627 | -76.409 |
Cash From Operating Activities | 25.368 | 21.118 | 14.012 | 7.066 | 3.905 |
Non-Cash Items | 146.443 | 103.177 | 361.202 | 14.048 | 4.156 |
Cash Taxes Paid | 3.925 | 8.66 | 0.28 | -0.022 | -0.006 |
Cash Interest Paid | 0.841 | 1.222 | 1.67 | 2.25 | 1.824 |
Changes in Working Capital | -39.417 | -87.445 | -50.381 | 44.764 | 28.015 |
Cash From Investing Activities | -350.887 | -106.729 | -38.394 | -42.767 | -6.709 |
Capital Expenditures | -131.661 | -101.278 | -38.394 | -42.767 | -6.709 |
Cash From Financing Activities | 15.817 | 35.297 | 468.906 | 414.59 | 105.367 |
Financing Cash Flow Items | -5.409 | -5.028 | -5.848 | 0 | |
Issuance (Retirement) of Stock, Net | 21.226 | 40.325 | 506.01 | 414.59 | 86.628 |
Issuance (Retirement) of Debt, Net | 0 | 0 | -31.256 | 0 | 18.739 |
Foreign Exchange Effects | -0.044 | 0.234 | -0.463 | -0.045 | -0.018 |
Net Change in Cash | -368.72 | -92.571 | 212.151 | 406.405 | 22.231 |
Other Investing Cash Flow Items, Total | -219.226 | -5.451 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -50.747 | -166 | -148.785 | -106.871 | -42.413 |
Cash From Operating Activities | -4.125 | -33.606 | -47.329 | -37.765 | -20.802 |
Cash From Operating Activities | 6.482 | 25.368 | 18.847 | 12.691 | 6.191 |
Non-Cash Items | 46.1 | 146.443 | 102.681 | 66.548 | 28.014 |
Cash Taxes Paid | 2.547 | 3.925 | 3.649 | 3.319 | 2.9 |
Cash Interest Paid | 0.436 | 0.841 | 0.841 | 0.841 | 0.841 |
Changes in Working Capital | -5.96 | -39.417 | -20.072 | -10.133 | -12.594 |
Cash From Investing Activities | 119.956 | -350.887 | -317.715 | -285.085 | -257.558 |
Capital Expenditures | -5.282 | -131.661 | -91.927 | -55.355 | -28.136 |
Other Investing Cash Flow Items, Total | 125.238 | -219.226 | -225.788 | -229.73 | -229.422 |
Cash From Financing Activities | -3.414 | 15.817 | 10.816 | 8.777 | 2.417 |
Financing Cash Flow Items | -5.814 | -5.409 | -5.409 | -5.409 | -5.409 |
Issuance (Retirement) of Stock, Net | 2.4 | 21.226 | 16.225 | 14.186 | 7.826 |
Issuance (Retirement) of Debt, Net | 0 | ||||
Foreign Exchange Effects | 0.024 | -0.044 | -0.295 | -0.21 | -0.018 |
Net Change in Cash | 112.441 | -368.72 | -354.523 | -314.283 | -275.961 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
10x Genomics, Inc. Company profile
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.Industry: | Laboratory Diagnostic & Testing Substances |
6230 Stoneridge Mall Road
PLEASANTON
CALIFORNIA 94588
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com